Doxorubicin in Liposomes for Pancreatic Cancer Treatment
Author Information
Author(s): J Vaage, D Donovan, P Uster, P Working
Primary Institution: Roswell Park Cancer Institute
Hypothesis
Does encapsulating doxorubicin in polyethylene glycol-coated liposomes improve its therapeutic efficacy against pancreatic carcinoma?
Conclusion
Liposomal doxorubicin was significantly more effective in inhibiting tumor growth compared to free doxorubicin in saline.
Supporting Evidence
- Liposomal doxorubicin showed a sixfold increase in drug accumulation at the tumor site compared to free doxorubicin.
- The liposomal formulation resulted in a higher number of tumor-free mice at necropsy.
- Confocal microscopy demonstrated greater retention of doxorubicin in tumors when encapsulated in liposomes.
Takeaway
This study found that a special type of medicine called liposomal doxorubicin works better at fighting cancer than the regular version of the medicine.
Methodology
The study involved injecting two formulations of doxorubicin into mice with human pancreatic tumors and measuring tumor growth and drug uptake.
Limitations
The study was conducted in mice, which may not fully represent human responses.
Participant Demographics
The study used athymic nude Swiss mice, which are commonly used in cancer research.
Statistical Information
P-Value
0.0083
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website